Related Experiment Video
Updated: Feb 25, 2026
12:13
Assessing Primary Motor Cortex Excitability and Excitability Modulation by Pairing Transcranial Magnetic Stimulation with Electromyography
Published on: October 7, 2025
764
ANMCO/ELAS/SIBioC Consensus Document: biomarkers in heart failure.
Nadia Aspromonte1, Michele Massimo Gulizia2, Aldo Clerico3
1CCU-Cardiology Department, Presidio Ospedaliero San Filippo Neri, Via Martinotti, 20, 00135 Rome, Italy.
Summary
New biomarkers aid heart failure (HF) evaluation and management beyond natriuretic peptides. A multi-biomarker approach promises tailored HF care for individual patient phenotypes.
Area of Science:
- Cardiology
- Biochemistry
- Clinical Medicine
Background:
- Biomarkers are crucial for evaluating and managing heart failure (HF).
- Natriuretic peptides (BNP, NT-proBNP) are established gold standards for HF diagnosis and prognosis.
- Emerging biomarkers reflect diverse HF pathophysiological processes like myocardial insult, inflammation, fibrosis, and remodeling.
Purpose of the Study:
- To review the evolving role of biomarkers in heart failure management.
- To explore the potential of novel biomarkers in identifying early renal dysfunction and cardio-renal syndrome.
- To advocate for a multi-biomarker approach for personalized HF patient care.
Main Methods:
- Review of current literature on HF biomarkers.
- Analysis of emerging biomarkers and their pathophysiological relevance.
- Discussion of the clinical utility and validation status of new biomarkers.
Main Results:
- Natriuretic peptides remain the gold standard for HF diagnosis and prognosis.
- Numerous new biomarkers are emerging, reflecting various HF pathways.
- Some novel biomarkers show promise for managing cardio-renal syndrome.
- The clinical roles of many new biomarkers require further validation.
Conclusions:
- A multi-biomarker strategy is essential for comprehensive HF patient evaluation.
- Personalized HF management can be achieved by tailoring care to individual pathological phenotypes.
- Enhanced collaboration between cardiologists and laboratories is needed for a multi-biomarker approach.
